A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
NCT07722546
Autoimmune Diseases, Endocrine System Diseases
View Trial DetailsNCT Number: NCT06357494
All cases of the study will be diagnosed as Graves' by History, examination, laboratory (FT3, FT4, TSH & TRAbs), X-ray on left wrist for bone age, neck grey scale ultrasonography for thyroid gland size, shape, echotexture, vascularity and nodule characters if present with TIRAD score calculation.
Then Color flow doppler ultrasound will be done to asses thyroid volume, number of vessels per square cm and inferior thyroid artery peak systolic velocity, end diastolic velocity and resistive index. Patients then will receive carbimazole antithyroid drug at dose 0.25-0.5 mg/kg/day PO & the dose will be titrated according to thyroid function test after 4-6 weeks.
Beta-adrenergic blockade will be added to all symptomatic cases. Regular follow up will be done every month of first 3 months of diagnosis and then every 3 months for 2 years by clinical and thyroid function test to asses response, compliance, complications, drug side effects, remission and relapses.
Doppler ultrasound will be done at 0, 12 and 24 months.
Trial opening soon.
Get Notified1 year–18 year
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 years
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Contact information is provided by the study sponsor or research team.
Assiut University
Other
Assessment of Thyroid Doppler Ultrasound in Relation to Clinical and Laboratory Parameters in Follow up of Pediatric Graves' Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07722546
Autoimmune Diseases, Endocrine System Diseases
View Trial DetailsNCT07682896
Autoimmune Diseases, Endocrine System Diseases
Gilbert, Arizona, United States
View Trial DetailsNCT07018323
Autoimmune Diseases, Endocrine System Diseases
Tucson, Arizona, United States
View Trial DetailsNCT07286006
Autoimmune Diseases, Endocrine System Diseases
Phoenix, Arizona, United States
View Trial Details